Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price traded up 10.6% during mid-day trading on Thursday . The company traded as high as $20.35 and last traded at $20.16. 285,948 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,141,996 shares. The stock had previously closed at $18.23.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CAPR. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 price target for the company. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Finally, Oppenheimer reiterated an "outperform" rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $24.67.
Check Out Our Latest Report on CAPR
Capricor Therapeutics Price Performance
The company has a market cap of $858.70 million, a price-to-earnings ratio of -21.61 and a beta of 4.00. The firm has a 50-day moving average price of $13.22 and a 200 day moving average price of $7.82.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. On average, equities analysts anticipate that Capricor Therapeutics Inc will post -1.17 EPS for the current fiscal year.
Insider Buying and Selling
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm's stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.00% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics during the first quarter worth about $40,000. SG Americas Securities LLC acquired a new position in Capricor Therapeutics during the third quarter valued at approximately $133,000. Main Street Financial Solutions LLC lifted its stake in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock valued at $1,040,000 after purchasing an additional 13,762 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
